Table 4.
Prostate cancer susceptibility stratified by Gleason score, T-stage, and serum PSA levels at diagnosis (control vs. SPCa)
| Genotype | Gleason score ≤ 7 (N = 241) |
Gleason score ≥ 8 (N = 150) |
||||
| OR* | 95% CI | p value | OR* | 95% CI | p value | |
| rs1447295 | ||||||
| CC | 1.0 | reference | 1.0 | reference | ||
| CA | 1.62 | 1.08 – 2.42 | 0.02 | 1.48 | 0.94 – 2.34 | 0.09 |
| AA | 1.09 | 0.46 – 2.56 | 0.84 | 1.63 | 0.66 – 3.92 | 0.29 |
| CA + AA | 1.53 | 1.04 – 2.25 | 0.03 | 1.50 | 0.97 – 2.32 | 0.07 |
| rs6983267 | ||||||
| TT | 1.0 | reference | 1.0 | reference | ||
| TG | 0.93 | 0.62 – 1.39 | 0.73 | 0.90 | 0.57 – 1.42 | 0.66 |
| GG | 1.84 | 0.96 – 3.55 | 0.07 | 2.41 | 1.20 – 4.86 | 0.01 |
| TG + GG | 1.05 | 0.72 – 1.55 | 0.79 | 1.10 | 0.72 – 1.69 | 0.67 |
| Genotype | T1 or T2 (N = 167) |
T3 or T4 (N = 224) |
||||
| OR* | 95% CI | p value | OR* | 95% CI | p value | |
| rs1447295 | ||||||
| CC | 1.0 | reference | 1.0 | reference | ||
| CA | 1.39 | 0.88 – 2.17 | 0.15 | 1.70 | 1.14 – 2.56 | 0.01 |
| AA | 1.34 | 0.53 – 3.29 | 0.53 | 1.28 | 0.55 – 2.95 | 0.57 |
| CA + AA | 1.38 | 0.90 – 2.11 | 0.14 | 1.64 | 1.11 – 2.41 | 0.01 |
| rs6983267 | ||||||
| TT | 1.0 | reference | 1.0 | reference | ||
| TG | 0.96 | 0.61 – 1.51 | 0.87 | 0.91 | 0.61 – 1.36 | 0.65 |
| GG | 2.68 | 1.37 – 5.30 | 4.0 × 10-3 | 1.69 | 0.87 – 3.31 | 0.12 |
| TG + GG | 1.19 | 0.78 – 1.83 | 0.42 | 1.02 | 0.69 – 1.49 | 0.93 |
| Genotype | PSA < 20 ng/mL (N = 208) |
PSA ≥ 20 ng/mL (N = 183) |
||||
| OR* | 95% CI | p value | OR* | 95% CI | p value | |
| rs1447295 | ||||||
| CC | 1.0 | reference | 1.0 | reference | ||
| CA | 1.46 | 0.95 – 2.23 | 0.08 | 1.71 | 1.12 – 2.60 | 0.01 |
| AA | 0.97 | 0.37 – 2.44 | 0.95 | 1.69 | 0.74 – 3.83 | 0.21 |
| CA + AA | 1.38 | 0.92 – 2.08 | 0.12 | 1.70 | 1.14 – 2.54 | 9.0 × 10-3 |
| rs6983267 | ||||||
| TT | 1.0 | reference | 1.0 | reference | ||
| TG | 0.96 | 0.63 – 1.47 | 0.86 | 0.92 | 0.60 – 1.40 | 0.69 |
| GG | 1.46 | 0.72 – 2.96 | 0.30 | 2.74 | 1.45 – 5.24 | 2.0 × 10-3 |
| TG + GG | 1.03 | 0.69 – 1.55 | 0.88 | 1.16 | 0.78 – 1.73 | 0.47 |
| Genotype | Nonaggressive (N = 99) |
Aggressivea (N = 292) |
||||
| OR* | 95% CI | p value | OR* | 95% CI | p value | |
| rs1447295 | ||||||
| CC | 1.0 | reference | 1.0 | reference | ||
| CA | 1.69 | 0.98 – 2.91 | 0.06 | 1.54 | 1.06 – 2.25 | 0.02 |
| AA | 1.39 | 0.44 – 3.99 | 0.56 | 1.28 | 0.59 – 2.81 | 0.53 |
| CA + AA | 1.64 | 0.97 – 2.75 | 0.06 | 1.50 | 1.05 – 2.15 | 0.03 |
| rs6983267 | ||||||
| TT | 1.0 | reference | 1.0 | reference | ||
| TG | 0.99 | 0.58 – 1.71 | 0.97 | 0.93 | 0.64 – 1.36 | 0.72 |
| GG | 1.45 | 0.58 – 3.46 | 0.42 | 2.32 | 1.29 – 4.26 | 0.01 |
| TG + GG | 1.05 | 0.63 – 1.78 | 0.85 | 1.12 | 0.79 – 1.60 | 0.52 |
OR*, Age-adjusted odds ratio.
a Aggressive, Gleason score ≥ 8, and/or T-stage T3 or T4, and/or PSA ≥ 20 ng/mL.